StockData
Bicara Therapeutics Inc. logo

Bicara Therapeutics Inc. (BCAX) stock

BCAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$9.60−0.15 (-1.54%)

Close on Nov 17, 2026Market cap $635.26MP/E –Yield –

Bicara Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Bicara Therapeutics's price to book ratio was 1.5× on Nov 11, 2026, against 2.5× a year earlier. Over the last 2 years it ranged from 1.1× to 3.8×, with a median of 2.0×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.5×−0.8
2025Dec 31, 20252.3×+0.4
2024Dec 31, 20241.9×–

More Bicara Therapeutics figures

See a number that looks wrong?